MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Jingwen Liu,1 Tingting Meng,1 Ming Yuan,1 Lijuan Wen,1 Bolin Cheng,1 Na Liu,1 Xuan Huang,2 Yun Hong,3 Hong Yuan,1 Fuqiang Hu1 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 2Department of Pharmacy, School of Medicine Science, Jiaxing University, Jia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu J, Meng T, Yuan M, Wen LJ, Cheng BL, Liu N, Huang X, Hong Y, Yuan H, Hu FQ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	breast cancer stem cells microRNA-200c paclitaxel solid lipid nanoparticles nanostructured lipid carriers combination therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/639584c25f5540fdac93b03a7b940fbc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:639584c25f5540fdac93b03a7b940fbc
record_format	dspace
spelling	oai:doaj.org-article:639584c25f5540fdac93b03a7b940fbc2021-12-02T07:36:52ZMicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell1178-2013https://doaj.org/article/639584c25f5540fdac93b03a7b940fbc2016-12-01T00:00:00Zhttps://www.dovepress.com/microrna-200c-delivered-by-solid-lipid-nanoparticles-enhances-the-effe-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jingwen Liu,1 Tingting Meng,1 Ming Yuan,1 Lijuan Wen,1 Bolin Cheng,1 Na Liu,1 Xuan Huang,2 Yun Hong,3 Hong Yuan,1 Fuqiang Hu1 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 2Department of Pharmacy, School of Medicine Science, Jiaxing University, Jiaxing, 3The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China Background: One of the major obstacles in the treatment of breast cancer is breast cancer stem cells (BCSC) which are resistant to standard chemotherapeutic drugs. It has been proven that microRNA-200c (miR-200c) can restore sensitivity to microtubule-targeting chemotherapeutic drugs by reducing the expression of class III β-tubulin. In this study, combination therapy with miR-200c and paclitaxel (PTX) mediated by lipid nanoparticles was investigated as an alternative strategy against BCSC. Materials and methods: A cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane was strategically selected to formulate solid lipid nanoparticles (SLN) for miR-200c delivery. Nanostructured lipid carriers (NLC) with 20 wt% oleic acid were prepared for PTX delivery. Mammospheres, which gained the characteristics of BCSC, were used as a cell model to evaluate the efficiency of combination therapy. Results: The cationic SLN could condense anionic miRNA to form SLN/miRNA complexes via charge interactions and could protect miRNA from degradation by ribonuclease. SLN/miR-200c complexes achieved 11.6-fold expression of miR-200c after incubation for 24 hours, compared with that of Lipofectamine™ 2000/miR-200c complexes (P<0.05). Intracellular drug release assay proved that miRNA can be released from SLN/miRNA complexes efficiently in 12 hours after cellular uptake. After BCSC were transfected with SLN/miR-200c, the expression of class III β-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (*P<0.01). Conclusion: The results indicated that the cationic SLN could serve as a promising carrier for miRNA delivery. In addition, the combination therapy of miR-200c and PTX revealed a novel therapeutic strategy for the treatment of BCSC. Keywords: breast cancer stem cells, microRNA-200c, paclitaxel, solid lipid nanoparticles, nanostructured lipid carriers, combination therapyLiu JMeng TYuan MWen LJCheng BLLiu NHuang XHong YYuan HHu FQDove Medical Pressarticlebreast cancer stem cellsmicroRNA-200cpaclitaxelsolid lipid nanoparticlesnanostructured lipid carrierscombination therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 6713-6725 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer stem cells microRNA-200c paclitaxel solid lipid nanoparticles nanostructured lipid carriers combination therapy Medicine (General) R5-920
spellingShingle	breast cancer stem cells microRNA-200c paclitaxel solid lipid nanoparticles nanostructured lipid carriers combination therapy Medicine (General) R5-920 Liu J Meng T Yuan M Wen LJ Cheng BL Liu N Huang X Hong Y Yuan H Hu FQ MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
description	Jingwen Liu,1 Tingting Meng,1 Ming Yuan,1 Lijuan Wen,1 Bolin Cheng,1 Na Liu,1 Xuan Huang,2 Yun Hong,3 Hong Yuan,1 Fuqiang Hu1 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 2Department of Pharmacy, School of Medicine Science, Jiaxing University, Jiaxing, 3The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China Background: One of the major obstacles in the treatment of breast cancer is breast cancer stem cells (BCSC) which are resistant to standard chemotherapeutic drugs. It has been proven that microRNA-200c (miR-200c) can restore sensitivity to microtubule-targeting chemotherapeutic drugs by reducing the expression of class III β-tubulin. In this study, combination therapy with miR-200c and paclitaxel (PTX) mediated by lipid nanoparticles was investigated as an alternative strategy against BCSC. Materials and methods: A cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane was strategically selected to formulate solid lipid nanoparticles (SLN) for miR-200c delivery. Nanostructured lipid carriers (NLC) with 20 wt% oleic acid were prepared for PTX delivery. Mammospheres, which gained the characteristics of BCSC, were used as a cell model to evaluate the efficiency of combination therapy. Results: The cationic SLN could condense anionic miRNA to form SLN/miRNA complexes via charge interactions and could protect miRNA from degradation by ribonuclease. SLN/miR-200c complexes achieved 11.6-fold expression of miR-200c after incubation for 24 hours, compared with that of Lipofectamine™ 2000/miR-200c complexes (P<0.05). Intracellular drug release assay proved that miRNA can be released from SLN/miRNA complexes efficiently in 12 hours after cellular uptake. After BCSC were transfected with SLN/miR-200c, the expression of class III β-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (*P<0.01). Conclusion: The results indicated that the cationic SLN could serve as a promising carrier for miRNA delivery. In addition, the combination therapy of miR-200c and PTX revealed a novel therapeutic strategy for the treatment of BCSC. Keywords: breast cancer stem cells, microRNA-200c, paclitaxel, solid lipid nanoparticles, nanostructured lipid carriers, combination therapy
format	article
author	Liu J Meng T Yuan M Wen LJ Cheng BL Liu N Huang X Hong Y Yuan H Hu FQ
author_facet	Liu J Meng T Yuan M Wen LJ Cheng BL Liu N Huang X Hong Y Yuan H Hu FQ
author_sort	Liu J
title	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
title_short	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
title_full	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
title_fullStr	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
title_full_unstemmed	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
title_sort	microrna-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/639584c25f5540fdac93b03a7b940fbc
work_keys_str_mv	AT liuj microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT mengt microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT yuanm microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT wenlj microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT chengbl microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT liun microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT huangx microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT hongy microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT yuanh microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell AT hufq microrna200cdeliveredbysolidlipidnanoparticlesenhancestheeffectofpaclitaxelonbreastcancerstemcell
_version_	1718399339810783232

MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Ejemplares similares